# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approv...
HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 pr...
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(...
atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to tr...
Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.